RG 012

Drug Profile

RG 012

Alternative Names: RG 456070; RG012; SAR 339375

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regulus Therapeutics; Sanofi
  • Developer Regulus Therapeutics
  • Class Antisense oligoribonucleotides; MicroRNAs; Urologics
  • Mechanism of Action MicroRNA inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hereditary nephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hereditary nephritis

Most Recent Events

  • 05 Jul 2018 Regulus Therapeutics halts the recruitment activities in Alport syndrome due to ongoing discussions with Sanofi regarding restructuring of partnership
  • 07 Nov 2017 Regulus initiates enrolment in a phase I renal biopsy trial for Hereditary nephritis
  • 04 May 2017 Preliminary adverse events and pharmacokinetics data from the phase I MAD trial in healthy volunteers released by Regulus Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top